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Abstract
Background of objective: The co-infbction of the Human Intmunodeflciency Virus and the
lactors of HCV and HBV caLrscs the development of hepatotoxicity. In patiants witlr HIV and
occult hepatitis C tltc active retro-virus treatment (llAART) colles along with hepatotoxicity
and leads to negative inrpairrrerrts in patients sLrfI'ering fiom HIV/HCV. The following
research identifies cases suff'ering fi'om occult hepatitis C in patients r.vith HIV. hundred
patierrts with hurnan immuttodeficiency virr-rs (FIIV) were enrolled in this cross-sectional
study.
Methods: l'he level of ALT. AST, ALK e ltz1,11s5 have been rneasured and the presence of
HCV-RNA in PBMCs rvith the rrethod of Nested-PCR arrd the detection of I{CV-RNA in the
plasma samples of HIV positive patients and also the detenrination of HCV genotypes in
positive samples of PBMCs with the method rvas conducted using RT-PCR .
R"^rufts, fu o1 lll pafilnk, // w/ink (z%l rtele su#nllg f'ont t/te co-nfrctbn
IilV/HCV. The HCV-RNAwas found in PBMCs specimens irr 9 patients (a0.9%) outof the
total 22 patients. also l3 patients (59.1%) outof 22 cases u'itl.t detectable HCV-RNA plasr.na.
HCV genotyping anatysis showed that 4 patients (44/%) were infected r,vith HCV subtype
3a,1 (1 1.1%) was infected rvith HCV subtype la and 2 cases (22.2%) u'as infected with FICV
sr-rbtype 1b. This study revealed the incidence of occult hepatitis C (40.9%) in HIV-infected
patients.ViraI load and plasrna genotpe cotnpared Lt patients with HIV/HCV co-infection.
There is no significant relationship between the type of genotype and viral load based on
statisticsl results(p:0.47). This str.rdy has shor'vn the incidence of occult HCV in HIV positive
patients. ln patients with HIV and co-infectiorr with hepatitis C. the level of liver enzyrnes
rvas significantly higher in 1o/o than in patients with HIV alone(pr<0.01).
Conciusion: By doing firrther research in order to discover and elirninate the factors of
danger and darrage of the liver during tlre treatmet. it is possible to prevent the possible derth
related to HIV.
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